BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration

From Yahoo Finance: 2025-06-02 10:16:00

German vaccine maker BioNTech announced a collaboration with Bristol Myers Squibb, causing BioNTech’s U.S.-listed shares to surge over 15%. Bristol Myers Squibb will pay $1.5 billion up front, with potential future payments totaling up to $9.6 billion based on milestones. The partnership aims to develop and sell BNT327, a drug in trials to treat various cancerous tumors. The companies plan to share manufacturing costs and profits or losses. BioNTech CEO Dr. Ugur Sahin expressed excitement about accelerating BNT327’s development with the collaboration. BioNTech’s shares rose 17% in early trading, while Bristol Myers Squibb stock saw a slight decline.

Read more: BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration